C-IDDApartial reprogramming, senolytic polyphenols, longevity diagnostics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Provide lower-cost biomarker testing for longevity diagnostics.
Diagnostic platform for affordable biomarker testing.
Listed as the company's longevity diagnostics platform.
Develop a cancer reprogramming therapy focused on glioblastoma by addressing epigenetic damage and cellular reprogramming.
Preclinical epigenetic/cellular reprogramming therapeutic program for cancer, specifically glioblastoma.
Listed as the company's lead preclinical cancer reprogramming therapy.
Develop affordable longevity diagnostics using biomarker testing.
Diagnostic platform approach for lower-cost longevity biomarker measurement.
Listed in the company pipeline alongside AgeQuant.
Address aging and cancer through epigenetic damage repair and cellular reprogramming.
Partial cellular reprogramming approach targeting epigenetic damage.
Listed in the company pipeline.
Develop Procyanidin C1 as a senolytic polyphenol compound for longevity-related applications.
Polyphenol-based senolytic compound program.
Listed in the company pipeline as PCC1 under senolytic research.
Develop senolytic polyphenol compounds for longevity applications.
Research and development of senolytic polyphenol compounds, including Procyanidin C1/PCC1.
Listed in the company pipeline alongside PCC1.